Roth Capital Begins Coverage on Fate Therapeutics Inc. (FATE)
Equities research analysts at Roth Capital initiated coverage on shares of Fate Therapeutics Inc. (NASDAQ:FATE) in a report issued on Thursday. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.
FATE has been the subject of several other research reports. BMO Capital Markets set a $4.00 price target on shares of Fate Therapeutics and gave the company a “buy” rating in a report on Monday, August 8th. Zacks Investment Research upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a report on Thursday, August 11th. Leerink Swann restated an “outperform” rating and set a $4.00 target price on shares of Fate Therapeutics in a report on Tuesday, June 21st. Finally, HC Wainwright began coverage on shares of Fate Therapeutics in a report on Thursday, July 28th. They set a “buy” rating and a $9.00 target price for the company. Nine analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $6.29.
Shares of Fate Therapeutics (NASDAQ:FATE) opened at 3.18 on Thursday. The stock’s market cap is $91.88 million. The firm has a 50-day moving average of $2.65 and a 200-day moving average of $2.03. Fate Therapeutics has a 52-week low of $1.46 and a 52-week high of $7.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/roth-capital-begins-coverage-on-fate-therapeutics-inc-fate.html
Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.03. The company earned $1.03 million during the quarter, compared to analysts’ expectations of $1.02 million. Fate Therapeutics had a negative net margin of 699.10% and a negative return on equity of 90.94%. On average, equities analysts expect that Fate Therapeutics will post ($1.12) EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the company. Spark Investment Management LLC raised its position in Fate Therapeutics by 1.8% in the first quarter. Spark Investment Management LLC now owns 63,700 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,100 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Fate Therapeutics by 7.8% in the second quarter. Bank of New York Mellon Corp now owns 68,444 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 4,941 shares during the last quarter. Lombard Odier Asset Management USA Corp increased its stake in shares of Fate Therapeutics by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 256,426 shares of the biopharmaceutical company’s stock worth $436,000 after buying an additional 7,052 shares during the last quarter. Redmile Group LLC increased its stake in shares of Fate Therapeutics by 1.0% in the second quarter. Redmile Group LLC now owns 1,502,180 shares of the biopharmaceutical company’s stock worth $2,554,000 after buying an additional 15,200 shares during the last quarter. Finally, BlackRock Fund Advisors increased its stake in shares of Fate Therapeutics by 26.2% in the second quarter. BlackRock Fund Advisors now owns 75,572 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 15,701 shares during the last quarter. 48.71% of the stock is currently owned by institutional investors and hedge funds.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.